August 2, 2025

Data from Glycemic Control and Prostate Cancer Mortality Risk in Veterans with Type 2 Diabetes Mellitus

Puntos clave

Moderate glycemic control (HbA1c 7%-8%) lowers prostate cancer mortality risk by 23% compared to good control.
Poor glycemic control (HbA1c >8%) also shows a 15% lower risk of prostate cancer mortality compared to good control.
Analysis included 763,424 veterans diagnosed with type 2 diabetes mellitus across different racial and ethnic groups.
Findings indicate that glycemic control affects prostate cancer mortality, suggesting further research is needed for future interventions.

Resumen

AbstractThis retrospective cohort study of veterans diagnosed with diabetes mellitus evaluated the association between time-varying measures of glycemic control and the time to prostate cancer–specific mortality. Competing risk Cox regression models were developed to estimate the association of glycemic control and prostate cancer mortality for the entire sample and stratified by racial and ethnic groups. A total of 763,424 veterans with type 2 diabetes mellitus (T2DM) were included. In the fully adjusted models, moderate glycemic control hemoglobin A1c (HbA1c) 7%–8% was associated with a 23% (HR, 0.77; 95% confidence interval, 0.68–0.85) lower risk and poor glycemic control (HbA1c >8%) was associated with a 15% (HR, 0.85; 95% confidence interval, 0.71–0.99) lower risk of prostate cancer mortality compared with good glycemic control (HbA1c Significance:Unlike many other cancers, there is an inverse association between prostate cancer risk and T2DM diagnosis. In this large, retrospective study of male veterans with T2DM, we observed an inverse association between glycemic control and prostate cancer mortality. Further research is required to verify this relationship in prospective studies and identify the potential mechanisms contributing to these findings.

Me gusta

Guardar